Forsøgene involverede i alt 1657 patienter med sekundær progressiv dissemineret sklerose (EDSS- baselineværdier på 3- 6, 5, dvs. patienter, som var i stand til at gå).
Secondary progressive multiple sclerosis (SP-MS) Two controlled clinical trials with Extavia involving a total of 1,657 patients with secondary progressive multiple sclerosis (baseline EDSS 3 to 6.5, i. e. patients were able to walk) were performed.